Selective COX-2 inhibitors and risk of myocardial infarction.
about
Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysisAspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphismIncreased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data.Expression of 5-lipoxygenase in human colorectal cancerAnimal products, diseases and drugs: a plea for better integration between agricultural sciences, human nutrition and human pharmacologyCyclooxygenase-2 inhibition restored endothelium-mediated relaxation in old obese zucker rat mesenteric arteries.Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months.Systems pharmacology augments drug safety surveillanceCelecoxib pathways: pharmacokinetics and pharmacodynamics.The COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning.Host-mediated resolution of inflammation in periodontal diseases.Drug-induced thrombosis--experimental, clinical, and mechanistic considerations.Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.Atherosclerosis as a disease of failed endogenous repairDocosahexaenoic acid suppresses breast cancer cell metastasis by targeting matrix-metalloproteinases.Pathophysiology of cyclooxygenases in cardiovascular homeostasis.Drug-induced thrombosis: an update.Synthesis, toxicity study and anti-inflammatory effect of MHTP, a new tetrahydroisoquinoline alkaloid.Determination of anti-inflammatory activities of standardised preparations of plant- and mushroom-based foods.Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs.Preserving vascular prostacyclin levels by microsomal prostaglandin E(2) synthase isoform 1 inhibition: a new strategy for vasoprotection?Aspirin induces autophagy via inhibition of the acetyltransferase EP300.
P2860
Q28200524-2B1390FD-812C-4F72-A417-C70C07E2EB65Q28217995-60B0BBA2-8205-40C4-92E8-F490EC24C2BAQ33516685-75410A54-3B49-47E9-B9BE-90C065D1ADA3Q33869146-8E31FA74-CF39-44E7-BF9E-B0E3D2D3DC35Q34541077-7CEB12DE-C3C1-40A2-9CC9-4CEE421D017BQ34691844-14351834-0282-47D6-8BFF-49506952A112Q34808175-6AAE9338-52D5-4BAF-8AA3-9F8C91F29D1BQ35075939-8A33A540-4B97-44EA-B54C-A5C175A6C441Q35830941-B730E413-F1A8-44B0-8B0B-6031D0C51D18Q36109838-F1831476-7A0B-4BA4-B109-0862700E1BCCQ36362712-566B9FBB-2D8F-4777-AB63-BD3AB8A8044EQ36762200-26E1B807-9479-4513-B09C-F3172B8C0FEDQ36904910-1A809349-D9E8-4376-AD9E-7C4D8928C0BDQ37152177-0CDCA983-FD41-4834-84A4-F4016404E708Q37580346-B0A70B70-EBE1-4F11-895D-298C1D148D38Q37736991-56C0946B-E7EE-4FB3-B397-C18C775643D1Q38103820-C3BF2840-684D-4A9D-A766-84B4FBBE9F29Q38981137-8F89EEEF-FADE-475A-9F80-CF82246D5B19Q39154883-19E5D934-0520-42AF-908B-7C6B63CF7EEEQ41969297-7FA9B575-89CB-4E09-A35A-038DBAB93954Q53554565-3E06F77C-DB62-483A-A33A-F81FF1A41E6AQ55255346-407F2A14-4328-47AF-A4C3-C2F3ECB1E654
P2860
Selective COX-2 inhibitors and risk of myocardial infarction.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Selective COX-2 inhibitors and risk of myocardial infarction.
@ast
Selective COX-2 inhibitors and risk of myocardial infarction.
@en
type
label
Selective COX-2 inhibitors and risk of myocardial infarction.
@ast
Selective COX-2 inhibitors and risk of myocardial infarction.
@en
prefLabel
Selective COX-2 inhibitors and risk of myocardial infarction.
@ast
Selective COX-2 inhibitors and risk of myocardial infarction.
@en
P2093
P2860
P356
P1476
Selective COX-2 inhibitors and risk of myocardial infarction.
@en
P2093
Florian Krotz
Hae-Young Sohn
Thomas M Schiele
Volker Klauss
P2860
P304
P356
10.1159/000086459
P577
2005-06-20T00:00:00Z